Why the study?
Does paricalcitol and dietary sodium restriction reduce residual albuminuria in patients with nondiabetic CKD on maximal ramipril therapy?
Does paricalcitol and dietary sodium restriction reduce residual albuminuria in patients with nondiabetic CKD on maximal ramipril therapy?
Moderate dietary sodium restriction substantially reduces residual albuminuria in nondiabetic CKD patients on maximal ACE inhibition, whereas the addition of paricalcitol provides no significant additional benefit in the intention-to-treat population.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Michael H. Hastings (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: